This is Swelife
Swelife supports collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
It is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners.
Swelife is a facilitator. Through a long-term, national perspective our work aims to contribute to these effects:
- The knowledge and resources within life science in Sweden are utilised nationally through collaboration and coordination
- Sweden offers good conditions for sustainable growth and international competitiveness in the life science sector
- Citizens of Sweden have access to innovative, equal, and people-centred care
Life science in Sweden has a leading role in developments towards world-class health and sustainable growth.
Swelife facilitates and accelerates innovation and collaboration within life science – from ideas to benefits for society.
Budget and Support
More than 100 organisations from healthcare, academia and industry in Sweden currently support Swelife.
- 2018: SEK 65 million from Vinnova (+SEK 65 million in co-financing)
- 2017: SEK 55 million from Vinnova (+SEK 55 million in co-financing)
- 2016: SEK 40 million from Vinnova (+SEK 40 million in co-financing)
- 2015: SEK 30 million from Vinnova (+SEK 30 million in co-financing)
- 2014: SEK 9 million from Vinnova (+SEK 9 million in co-financing)
Swelife was established in the summer of 2014 when the Diabetes Agenda and SILS (Sweden as an International Centre for Life Science) jointly applied to launch a so-called strategic innovation area (SIO). The idea was to gather the Life Science regions in Sweden under one common national research and innovation agenda.
The SIO on non-communicable diseases was approved in May 2014, changed its name to Swelife in the autumn, and in January 2015 included an additional agenda (PMC – Personalised Medicine Cancer).
Swelife’s goals 2020
- Swelife engages – as a facilitator – stakeholders from the entire life science sector (academia, industry, healthcare and patients)
- Swelife has reinforced its international perspective
- Swelife has contributed to a national life science strategy
- Swelife has contributed to increasing the level of expertise within the life science sector, and to making it accessible
- SMEs and early-stage projects have access to more comprehensive financing, from idea to used product/service
- Swelife has contributed to better overview of, and access to, research infrastructure related to life science
- Swelife has enabled development and national dissemination of generic nationally scalable solutions for improved health
- Swelife has contributed to more structured and shareable data